Threshold, Amory Faulkner, oil on canvas 1 The prospects of elimination of HIV with test and treat strategy Mirjam Kretzschmar 1,2 Maarten Schim van der.

Slides:



Advertisements
Similar presentations
The analysis of survival data in nephrology. Basic concepts and methods of Cox regression Paul C. van Dijk 1-2, Kitty J. Jager 1, Aeilko H. Zwinderman.
Advertisements

Kessler, J. Myers, J.E. ; Nucifora, K.A. ; Mensah, N. ; Kowalski, A. ; Sweeney, M. ; Toohey, C. ; Shepard, C. ; Cutler, B. ; Braithwaite, R.S. Modeling.
R 0 and other reproduction numbers for households models MRC Centre for Outbreak analysis and modelling, Department of Infectious Disease Epidemiology.
National Institute for Public Health and the Environment HIV, HCV, and HBV in injecting drug users in Europe Mirjam Kretzschmar Centre for Infectious Disease.
What is Epidemiology? (1)
Syphilis Trends in the United States James D. Heffelfinger, MD, MPH Epidemiology and Surveillance Branch, DSTD Centers for Disease Control and Prevention.
How can Modeling Help in Emerging Epidemics? John Grefenstette, PhD Public Health Dynamics Lab Health Policy & Management Pitt Public Health Dec 5, 2014.
National Institute for Public Health and the Environment Comparison of network models for STI transmission and intervention: how useful are they for public.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Treatment as prevention (TASP) for HIV and HCV: The evidence and modelling Peter Vickerman.
Attaining Realistic and Substantial Reductions in HIV Incidence: Model Projections of Combining Microbicide and Male Circumcision interventions in Rural.
Accelerating Anti-Retroviral Treatment as a catalytic action for Ending AIDS Pride Chigwedere, MD, PhD Senior Advisor to the African Union AWA CONSULTATIVE.
Effects of heterogeneity in hosts and pathogens on effectiveness of vaccination Mirjam Kretzschmar RIVM, Department of Infectious Diseases Epidemiology.
1 Risks and Benefits of Home-Use HIV Test Kits Richard Forshee, Ph.D. U.S. Food and Drug Administration Center for Biologics Evaluation and Research Office.
Modeling the SARS epidemic in Hong Kong Dr. Liu Hongjie, Prof. Wong Tze Wai Department of Community & Family Medicine The Chinese University of Hong Kong.
Sex work among people who inject drugs in England, Wales & Northern Ireland: Findings from a National Survey of Health Harms and Behaviours Sara Croxford,
Higher antiretroviral treatment coverage is associated with lower HIV infection rates: analysis of 51 low and middle-income countries Andrew Hill, Liverpool.
Introduction to Epidemiology Manish Chaudhary. Basic Concept in Epidemiology Epidemiology is the study of the occurrence, distribution and determinants.
Estimation of the number of people with undiagnosed HIV infection in a country Andrew Phillips, UCL, London HIV in Europe Meeting 2 November 2009, Stockholm.
How does mass immunisation affect disease incidence? Niels G Becker (with help from Peter Caley ) National Centre for Epidemiology and Population Health.
Social diseases (HIV and tuberculosis) and population health in Russia Vladimir Kozlov NRU-Higher school of economics, BSPS Annual Conference, 08/09/11.
Matthew Fox Center for Global Health & Development Department of Epidemiology Boston University July 17, 2011 The first step is admitting you have a problem.
Creating an AIDS-Free Generation The beginning of the end of AIDS Center for Strategic & International Studies Washington, DC March 22, 2012 Thomas R.
Modelling the role of household versus community transmission of TB in Zimbabwe Georgie Hughes Supervisor: Dr Christine Currie (University of Southampton)
Benefits of PrEP as an adjunctive method of HIV prevention during attempted conception between HIV-uninfected women and HIV- infected male partners: A.
What do models estimate to be the impacts on HIV incidence of various percentages of people with HIV on ART ? National AIDS Trust Treatment as Prevention.
Phylogenetic Insight into HIV Transmission Networks in a Southeastern US Cohort Ann Dennis 1, Stéphane Hué 2, Christopher Hurt 1, Sonia Napravnik 1, Deenan.
Population-based impact of ART in high HIV prevalence settings Marie-Louise Newell Professor of Global Health Faculty of Medicine, Faculty of Social and.
To Increase Investment in Syringe Exchange in the U.S. would be Cost-saving. Results from modeling hypothetical syringe coverage levels INTL AIDS CONF.
Return on investment: How do whole societies benefit from improved services and coverage for key populations? Bradley Mathers Kirby Institute UNSW Australia.
Matthew Fox Center for Global Health & Development Department of Epidemiology Boston University Health Economics and Epidemiology Research Office July.
Does HIV serosorting increase syphilis prevalence among men who have sex with men in Western Europe? - A mathematical modelling study.
Stefan Ma1, Marc Lipsitch2 1Epidemiology & Disease Control Division
PhD We knew nothing about the set-point viral loads. What was unknown about HIV-1 infection before this paper was published in 2007? 1.Virus density.
HPTN 065 TLC-Plus: Feasibility of an enhanced test, link-to- care plus treat approach for HIV prevention in the U.S. HIV Research Catalyst Forum April.
CDC's Model for West Africa Ebola Outbreak Summarized by Li Wang, 11/14.
Understanding temporal trends in HIV prevalence, incidence and ARV Dr Valerie Delpech Head of HIV surveillance Public Health England.
 MSM, specifically HIV-positive MSM, have a high risk of anal cancer caused by human papillomavirus (HPV).  It has been suggested that MSM attending.
Decline in incidence of HIV and Hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction? 1. Julius Center, University.
Modeling ‘test and treat’ for HIV in South Africa Jan AC Hontelez 1,2,3, Mark N Lurie 4, Till Bärnighausen 3,5, Roel Bakker 1 Rob Baltussen 2, Frank Tanser.
HIV and STI Department, Health Protection Agency - Colindale HIV and AIDS Reporting System The threshold for an ART secondary prevention effect on HIV.
Drug users in Amsterdam: are they still at risk for HIV? Nienke van der Knaap, Bart Grady, Maarten Schim van der Loeff, Titia Heijman, Arjen Speksnijder,
ARV-Based Prevention: Perspective from Epidemiology & Modelling Tim Hallett Imperial College London.
The Contribution of Early HIV Infection to HIV Spread in Lilongwe, Malawi: Implications for Transmission Prevention Strategies Kimberly Powers, 1 Azra.
The Effects of Different ART Eligibility Strategies on HIV-Related Mortality and Incidence John Stover, Carel Pretorius, Lori Bollinger Futures Institute.
Prevention of HIV Transmission Treatment as Prevention or Behavior Change Interventions? Moderator Victoria A Cargill, M.D., M.S.C.E. Office of AIDS Research,
Knowledge of Rural Married Women on Prevention of Mother To Child Transmission (MTCT) HIV in Udupi. Mrs. Suja Karkada MCON, Manipal.
Zindoga Mukandavire Social and Mathematical Epidemiology Group London School of Hygiene and Tropical Medicine, UK Improving health worldwide
Evidence of international transmission of HCV in pan-European study of HIV- positive men who have sex with men (MSM). M Danta 1,9 *, T van de Laar 4 *,
Moving from a commodity approach: “Fund some of everything” or “Fund what is comfortable” to An Investment approach: “Fund evidenced-based activities.
Chlamydia screening programs: are epidemiology and mathematical modelling looking at the same thing? Nicola Low Institute of Social and Preventive Medicine.
Daouda Diouf Executive Director Enda Santé Dakar, Senegal
Timor-Leste Last updated: January 2016.
Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.
How complicated do we want to make this?
Changing demographics and the impact on dementia
Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study  Dr Brian G Williams, PhD, Somya Gupta, MA,
for the RODAM Consortium
IAEN Conference (20 July 2018)
Estimation of R(t). Estimation of R(t). (A) Daily R(t) as inferred from the daily incidence of new infections for one stochastic model realization. Tg.
The HIV Epidemic among People who Inject Drugs
The Fenway Institute, Fenway Health, Boston, MA
Progress and prospects for the control of HIV and tuberculosis in South Africa: a dynamical modelling study  Dr Brian G Williams, PhD, Somya Gupta, MA,
Key Affected Populations
Cost-effectiveness of scaling up mass drug administration for the control of soil- transmitted helminths: a comparison of cost function and constant costs.
HIV incidence in men who have sex with men in England and Wales 2001–10: a nationwide population study  Paul J Birrell, PhD, Prof O Noel Gill, FFPH, Valerie.
HIV Viral Suppression Rate in U. S
D. T. Hamilton, MPH PhD, S. M. Goodreau, PhD, S. M. Jenness, PhD, P. S
Strategic framework for TB/HIV
On behalf of the H-TEAM initiative
Presentation transcript:

Threshold, Amory Faulkner, oil on canvas 1 The prospects of elimination of HIV with test and treat strategy Mirjam Kretzschmar 1,2 Maarten Schim van der Loeff 3 Daniela de Angelis 4 Roel Coutinho 1,2 1 Centre for Infectious Disease Control, RIVM 2 University Medical Centre Utrecht, NL 3 Municipal Health Service, Amsterdam, NL 4 MRC Biostatistics Unit, Cambridge, UK 26July 2012 AIDS conference Washington DC

Test and treat strategy

Treatment and infectivity Cohen et al. NEJM 2011

From Granich et al. Lancet 2009 Elimination possible? Aims of our study: Modify and generalize the model to include knowledge on natural history Derive and analyze under what conditions elimination is possible

Generalized model structure Variable number of compartments with variable duration Variable infectivity -> better description of natural history including variable infectivity

Epidemic dynamics Exponential growth at the start of the epidemic, growth rate determined by R 0 Exponential decay at elimination, decay rate determined by R e Exponential growth Elimination Transient dynamics Epidemic growth and elimination are threshold phenomena => linear analysis

Analysis Determine explicit expressions for R 0 and R e from model equations Estimate disease progression parameters from data (CASCADE collaboration) Use information about distribution of infectivity (Hollingsworth et al. JID 2008) Relate infectivity to epidemic growth rate r and R 0 via generation interval distribution (Wallinga & Lipsitch 2007) Estimate r from incidence or doubling time at onset of epidemic From R 0 determine transmission parameter λ Elimination threshold is determined as function of coverage and adherence to treatment Assumption: populations and behaviors driving HIV transmission during growth phase also determine transmission dynamics during elimination.

3 infection stages Progression rates from CASCADE Infectivity from Hollingsworth 2008 Relationship r and R 0 :

Elimination threshold  Elimination threshold R e as function of transmission and intervention parameters  Elimination possible if R e < 1  From incidence or doubling time during exponential growth phase estimate r  From r compute R 0  Determine elimination threshold for given R 0  If more recent estimates of R 0 are available these can be used (e.g. from genetic data)

Elimination threshold  For R 0 > 6 elimination not possible  Elimination possible for low risk populations  For the coverage and drop out rate assumed by Granich elimination is feasible if R 0 <5 R 0 =

Estimates from literature Populationr (1/yr)R0R0 d (yrs)Data typeRef South Africa incidenceGranich 2009 France incidenceNishiura 2010 West Germany incidenceNishiura 2010 UK incidenceNishiura 2010 SSAC geneticWalker 2005 High income countries geneticWalker 2005 Albania geneticSalemi 2008 England & Wales incidenceGran 2008 Brazil geneticBello 2007 MSM Netherlands 2.39incidenceBezemer 2008

Conclusions  Elimination is a threshold phenomenon. Information about possible elimination can be obtained from epidemic growth rate and generation interval distribution.  Elimination is only feasible for populations with low basic reproduction numbers or if the reproduction number is lowered significantly as a result of other additional interventions.  High infectivity during primary infection significantly increases the elimination threshold.  If reliable estimates for R 0 could be obtained from phylogenetic analysis prospects of elimination could be quantified more reliably.

Acknowledgements Co-authors: Maarten Schim van der Loeff Infectious Disease Unit, Municipal Health Service Amsterdam, The Netherlands Daniela de Angelis MRC Biostatistics Unit, Cambridge UK Roel Coutinho Center for Infectious Disease Control, RIVM and University Medical Center Utrecht, The Netherlands CASCADE Collaboration Paul Birrell, MRC Biostatistics Unit, Cambridge UK